Research Papers:
SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2154 views | HTML 2635 views | ?
Abstract
Marta Mellai1,*, Monica Cattaneo2,*, Alessandra Maria Storaci2, Laura Annovazzi1, Paola Cassoni3, Antonio Melcarne4, Pasquale De Blasio6, Davide Schiffer1, Ida Biunno2,5
1Neuro-Bio-Oncology Center/Policlinico di Monza Foundation, Vercelli 13100, Italy
2Institute for Genetic and Biomedical Research, National Research Council, Milan 20138, Italy
3Department of Medical Sciences, University of Turin/Città della Salute e della Scienza, Turin 10126, Italy
4Department of Neurosurgery, CTO Hospital/Città della Salute e della Scienza, Turin 10126, Italy
5IRCCS-Multimedica, Milan 20138, Italy
6ISENET Stem Cell Bank, Milan 20138, Italy
*These authors have contributed equally to this work
Correspondence to:
Ida Biunno, e-mail: [email protected]
Keywords: brain tumors, glioblastoma multiforme, SEL1L, genetic variant, prognosis
Received: January 21, 2015 Accepted: March 14, 2015 Published: April 10, 2015
ABSTRACT
The suppressor of Lin-12-like (C. elegans) (SEL1L) is involved in the endoplasmic reticulum (ER)-associated degradation pathway, malignant transformation and stem cells.
In 412 formalin-fixed and paraffin-embedded brain tumors and 39 Glioblastoma multiforme (GBM) cell lines, we determined the frequency of five SEL1L single nucleotide genetic variants with regulatory and coding functions by a SNaPShot™ assay. We tested their possible association with brain tumor risk, prognosis and therapy.
We studied the in vitro cytotoxicity of valproic acid (VPA), temozolomide (TMZ), doxorubicin (DOX) and paclitaxel (PTX), alone or in combination, on 11 GBM cell lines, with respect to the SNP rs12435998 genotype.
The SNP rs12435998 was prevalent in anaplastic and malignant gliomas, and in meningiomas of all histologic grades, but unrelated to brain tumor risks. In GBM patients, the SNP rs12435998 was associated with prolonged overall survival (OS) and better response to TMZ-based radio-chemotherapy. GBM stem cells with this SNP showed lower levels of SEL1L expression and enhanced sensitivity to VPA.

PII: 3611